90. Retinitis pigmentosa Clinical trials / Disease details
Clinical trials : 147 / Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110
Showing 1 to 10 of 147 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02018692 (ClinicalTrials.gov) | March 1, 2024 | 17/12/2013 | The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Fun ... | The Effect of Oral Administration of 9-cis ß Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa The Effect of Oral Administration of 9-cis ß Carotene Rich Powder of the Alga Dunaliella Bardawil on ... | Retinitis Pigmentosa | Dietary Supplement: Alga Dunaliella Bardawil powder;Dietary Supplement: Placebo:Starch | Sheba Medical Center | NULL | Not yet recruiting | 12 Years | 18 Years | All | 30 | Phase 1/Phase 2 | Israel |
| 2 | NCT05537220 (ClinicalTrials.gov) | June 2023 | 8/9/2022 | Oral N-acetylcysteine for Retinitis Pigmentosa | NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study ... | Retinitis Pigmentosa | Drug: N-acetylcysteine;Drug: Placebo | Johns Hopkins University | National Eye Institute (NEI);Duke University;Emory University;Massachusetts Eye and Ear Infirmary;Mayo Clinic;Medical College of Wisconsin;Retina Foundation of the Southwest;Stanford University;University of California, Davis;University of Florida;University of Illinois at Chicago;University of Iowa;University of Miami;University of Michigan;University of Minnesota;University of Oklahoma;University of Southern California;University of Utah;University of Washington;University of Wisconsin, Madison;Vanderbilt University;Vitreo Retinal Associates, PA;University of Houston;Medical University of Graz;McGill University;Universität Tübingen;Centro Medico ABC;Radboud University Medical Center;University of Amsterdam;University Hospital, Basel, Switzerland;University College London Hospitals;Northwestern University National Eye Institute (NEI);Duke University;Emory University;Massachusetts Eye and Ear Infirmary;Ma ... | Not yet recruiting | 18 Years | 65 Years | All | 438 | Phase 3 | United States;Austria;Canada;Germany;Mexico;Netherlands;Switzerland;United Kingdom |
| 3 | NCT05282953 (ClinicalTrials.gov) | November 10, 2022 | 8/3/2022 | A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of Small Molecule KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa (ABACUS) A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of Small Molecule KIO-30 ... | A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of Small Molecule KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa (ABACUS) A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of Small Molecule KIO-30 ... | Retinitis Pigmentosa | Drug: KIO-301 | Kiora Pharmaceuticals, Inc. | NULL | Recruiting | 18 Years | 80 Years | All | 6 | Phase 1 | Australia |
| 4 | NCT05413148 (ClinicalTrials.gov) | August 5, 2022 | 28/5/2022 | The Effect of Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa The Effect of Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigme ... | The Effect of Wharton Jelly-derived Mesenchymal Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa The Effect of Wharton Jelly-derived Mesenchymal Stem Cells and Stem Cell Exosomes on Visual Function ... | Retinitis Pigmentosa | Biological: Subtenon injection of Wharton jelly derived mesenchymal stem cells;Biological: Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes;Other: Placebo Biological: Subtenon injection of Wharton jelly derived mesenchymal stem cells;Biological: Subtenon ... | TC Erciyes University | NULL | Recruiting | 18 Years | 70 Years | All | 135 | Phase 2/Phase 3 | Turkey |
| 5 | EUCTR2020-002873-88-IE (EUCTR) | 19/07/2022 | 15/10/2021 | Gene Therapy Trial for Patients with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defect on Chromosome X. Gene Therapy Trial for Patients with Retinitis Pigmentosa(progressive reduction in vision) due to a ... | Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene - Gene Therapy Trial for Patients with Retinitis Pigmentosa: RPGR Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigme ... | X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene MedDRA version: 20.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] X-Linked Retinitis Pigmentosacaused by mutations in the RPGR gene MedDRA version: 20.0;Level: PT;Cla ... | Product Name: Botaretigene Sparoparvovec Product Code: AAV5-hRKp.RPGR INN or Proposed INN: botaretigene sparoparvovec Other descriptive name: AAV5-HRKP.RPGR Product Name: Botaretigene Sparoparvovec Product Code: AAV5-hRKp.RPGR INN or Proposed INN: botaretigene sparoparvovec Other descriptive name: AAV5-HRKP.RPGR Product Name: Botaretigene Sparoparvovec Product Code: AAV5-hRKp.RPGR INN or Proposed INN: botaretigen ... | MeiraGTx UK II Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 96 | Phase 3 | United States;Spain;Ireland;Israel;Switzerland;Italy;United Kingdom;France;Canada;Belgium;Denmark;Netherlands;Germany United States;Spain;Ireland;Israel;Switzerland;Italy;United Kingdom;France;Canada;Belgium;Denmark;Ne ... | ||
| 6 | NCT05392179 (ClinicalTrials.gov) | July 14, 2022 | 28/3/2022 | A Study in Subjects With Retinitis Pigmentosa | An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: ADX-2191 | Aldeyra Therapeutics, Inc. | NULL | Recruiting | 18 Years | N/A | All | 8 | Phase 2 | United States |
| 7 | NCT05392751 (ClinicalTrials.gov) | June 2, 2022 | 23/5/2022 | Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With R ... | Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of ... | Retinitis Pigmentosa;Retinitis Pigmentosa Syndrome | Drug: EA-2353 | Endogena Therapeutics, Inc | NULL | Recruiting | 18 Years | N/A | All | 14 | Phase 1/Phase 2 | United States |
| 8 | EUCTR2020-002255-37-IE (EUCTR) | 26/05/2022 | 15/10/2021 | Long Term Follow-Up study of Gene Therapy Trial for Patients with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defect on Chromosome X. Long Term Follow-Up study of Gene Therapy Trial for Patients with Retinitis Pigmentosa(progressive r ... | Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene - Long Term Follow-Up study of Gene Therapy Trial for Patients with Retinitis Pigmentosa: RPGR Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis PigmentosaAssociat ... | X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene MedDRA version: 20.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] X-Linked Retinitis Pigmentosacaused by mutations in the RPGR gene MedDRA version: 20.0;Level: PT;Cla ... | Product Name: AAV5-hRKp.RPGR INN or Proposed INN: botaretigene sparoparvovec Other descriptive name: AAV5-HRKP.RPGR Product Name: AAV5-hRKp.RPGR INN or Proposed INN: botaretigene sparoparvovec Other descriptive name: AAV5-HRKP.RPGR Product Name: AAV5-hRKp.RPGR INN or Proposed INN: botaretigene sparoparvovec Other descriptive name: A ... | MeiraGTx UK II Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 66 | Phase 3 | United States;Spain;Ireland;Israel;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Denmark;Germany;Netherlands United States;Spain;Ireland;Israel;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Denmark;Ge ... | ||
| 9 | EUCTR2020-002873-88-ES (EUCTR) | 28/03/2022 | 02/11/2021 | Gene Therapy Trial for Patients with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defect on Chromosome X. Gene Therapy Trial for Patients with Retinitis Pigmentosa(progressive reduction in vision) due to a ... | Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene - Gene Therapy Trial for Patients with Retinitis Pigmentosa: RPGR Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigme ... | X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene MedDRA version: 20.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] X-Linked Retinitis Pigmentosacaused by mutations in the RPGR gene MedDRA version: 20.0;Level: PT;Cla ... | Product Name: AAV5-hRKp.RPGR INN or Proposed INN: botaretigene sparoparvovec Other descriptive name: AAV5-hRKp.RPGR Product Name: AAV5-hRKp.RPGR INN or Proposed INN: botaretigene sparoparvovec Other descriptive name: AAV5-hRKp.RPGR Product Name: AAV5-hRKp.RPGR INN or Proposed INN: botaretigene sparoparvovec Other descriptive name: A ... | MeiraGTx UK II Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 66 | Phase 3 | United States;Spain;Ireland;Israel;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Denmark;Germany;Netherlands United States;Spain;Ireland;Israel;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Denmark;Ge ... | ||
| 10 | EUCTR2020-002255-37-ES (EUCTR) | 28/03/2022 | 02/11/2021 | Long Term Follow-Up study of Gene Therapy Trial for Patients with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defect on Chromosome X. Long Term Follow-Up study of Gene Therapy Trial for Patients with Retinitis Pigmentosa(progressive r ... | Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene - Long Term Follow-Up study of Gene Therapy Trial for Patients with Retinitis Pigmentosa: RPGR Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis PigmentosaAssociat ... | X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene MedDRA version: 20.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] X-Linked Retinitis Pigmentosacaused by mutations in the RPGR gene MedDRA version: 20.0;Level: PT;Cla ... | Product Name: AAV5-hRKp.RPGR INN or Proposed INN: botaretigene sparoparvovec Other descriptive name: AAV5-hRKp.RPGR Product Name: AAV5-hRKp.RPGR INN or Proposed INN: botaretigene sparoparvovec Other descriptive name: AAV5-hRKp.RPGR Product Name: AAV5-hRKp.RPGR INN or Proposed INN: botaretigene sparoparvovec Other descriptive name: A ... | MeiraGTx UK II Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 66 | Phase 3 | United States;Spain;Ireland;Israel;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Denmark;Germany;Netherlands United States;Spain;Ireland;Israel;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Denmark;Ge ... |